Literature DB >> 35794839

Thrombocytopenia, anasarca, and severe inflammation.

Amanallah Montazeripouragha1, Christine M Campbell1, James Russell2, Nadia Medvedev3, Daniel R Owen3, Alison Harris2, Fergal Donnellan4, Iain McCormick5, David C Fajgenbaum6, Luke Y C Chen7.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 35794839      PMCID： PMC9555220          DOI： 10.1002/ajh.26651

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   13.265


× No keyword cloud information.
  26 in total

1.  Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease.

Authors:  Yujun Dong; Lu Zhang; Lin Nong; Lihong Wang; Zeyin Liang; Daobin Zhou; David C Fajgenbaum; Hanyun Ren; Jian Li
Journal:  Ann Hematol       Date:  2018-05-07       Impact factor: 3.673

2.  Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease.

Authors:  David C Fajgenbaum; Ruth-Anne Langan; Alberto Sada Japp; Helen L Partridge; Sheila K Pierson; Amrit Singh; Daniel J Arenas; Jason R Ruth; Christopher S Nabel; Katie Stone; Mariko Okumura; Anthony Schwarer; Fábio Freire Jose; Nelson Hamerschlak; Gerald B Wertheim; Michael B Jordan; Adam D Cohen; Vera Krymskaya; Arthur Rubenstein; Michael R Betts; Taku Kambayashi; Frits van Rhee; Thomas S Uldrick
Journal:  J Clin Invest       Date:  2019-08-13       Impact factor: 14.808

Review 3.  Approach to a patient with elevated serum alkaline phosphatase.

Authors:  Asma Siddique; Kris V Kowdley
Journal:  Clin Liver Dis       Date:  2012-04-06       Impact factor: 6.126

4.  Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease.

Authors:  Ruth-Anne Langan Pai; Alberto Sada Japp; Michael Gonzalez; Rozena F Rasheed; Mariko Okumura; Daniel Arenas; Sheila K Pierson; Victoria Powers; Awo Akosua Kesewa Layman; Charlly Kao; Hakon Hakonarson; Frits van Rhee; Michael R Betts; Taku Kambayashi; David C Fajgenbaum
Journal:  JCI Insight       Date:  2020-05-07

Review 5.  Malignancy-associated haemophagocytic lymphohistiocytosis.

Authors:  Audi Setiadi; Adi Zoref-Lorenz; Christina Y Lee; Michael B Jordan; Luke Y C Chen
Journal:  Lancet Haematol       Date:  2022-01-31       Impact factor: 18.959

Review 6.  Cytokine Storm.

Authors:  David C Fajgenbaum; Carl H June
Journal:  N Engl J Med       Date:  2020-12-03       Impact factor: 91.245

7.  Soluble interleukin-6 receptor in the COVID-19 cytokine storm syndrome.

Authors:  Luke Y C Chen; Catherine M Biggs; Shahin Jamal; Sophie Stukas; Cheryl L Wellington; Mypinder S Sekhon
Journal:  Cell Rep Med       Date:  2021-04-19

8.  Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease.

Authors:  Yoshito Nishimura; David C Fajgenbaum; Sheila K Pierson; Noriko Iwaki; Asami Nishikori; Mitsuhiro Kawano; Naoya Nakamura; Koji Izutsu; Kengo Takeuchi; Midori Filiz Nishimura; Yoshinobu Maeda; Fumio Otsuka; Kazuyuki Yoshizaki; Eric Oksenhendler; Frits van Rhee; Yasuharu Sato
Journal:  Am J Hematol       Date:  2021-07-28       Impact factor: 13.265

9.  TAFRO Syndrome Presenting with Retroperitoneal Panniculitis-like Computed Tomography Findings at Disease Onset.

Authors:  Ryo Yanagiya; Takuma Suzuki; Shuhei Nakamura; Kotaro Fujita; Midori Oyama; Ayumi Okuyama; Kunie Sugasawa; Takahiro Nakayama; Yoshihiro Suzuki; Kenichi Ishizawa; Soichi Saito
Journal:  Intern Med       Date:  2019-12-13       Impact factor: 1.271
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.